Moreover, CheckMate 568 is an open phase II study and aimed to evaluate the efficacy and safety of nivolumab combined with ipilimumab in the treatment of advanced/metastatic NSCLC, and to investigate the correlation between PD-L1 expression and TMB on the treatment efficacy (47). The gene discussed is CD274; the disease is non-small cell lung carcinoma.